Key Takeaways:
- When the Wegovy pill launched in January, telehealth provider LifeMD said its business doubled almost overnight, going from 300-400 new patients daily to 600-1,000
- Tens of thousands of people have started taking Novo Nordisk's Wegovy pill in the four months since it launched in the U.S., the majority of them new to the GLP-1 category
- Novo highlighted oral semaglutide's 17% weight loss compared to Lilly's pill at 12%, giving Novo a competitive edge over Foundayo
Wegovy Pill Creates Unexpected Market Boom
The launch of Novo Nordisk's oral Wegovy pill has sent shockwaves through the GLP-1 weight loss market, with early adoption numbers far exceeding Wall Street's expectations. When the Wegovy pill launched in January, telehealth provider LifeMD said its business doubled almost overnight, going from seeing between 300 and 400 new patients a day to 600 to 1,000 new patients a day, a level of interest that surprised even CEO Justin Schreiber.
This dramatic uptake represents more than a successful product launch — it's fundamentally changing how investors view the competitive landscape between the two GLP-1 giants. Tens of thousands of people have started taking Novo Nordisk's Wegovy pill in the four months since it launched in the U.S., the majority of them new to the GLP-1 category.
The surge in demand reflects a broader shift in how people approach GLP-1 medications for weight management. Many who previously avoided treatment due to injection anxiety are now finding oral options more appealing and accessible.
Manufacturing Concerns Turn Into Market Advantages
Novo's Wegovy pill uses the same main ingredient as its weekly shot, and the company had at times struggled to produce enough of the peptide to satisfy the soaring demand for the injection, with the oral formulation requiring even more of it. Many analysts initially viewed this as a potential weakness compared to Lilly's approach.
Meanwhile, Lilly was telling investors its GLP-1 pill was easier to make and wouldn't face the shortages that hindered the shots. However, Novo's successful supply management and the pill's strong efficacy data have turned what seemed like a disadvantage into a competitive moat.
The manufacturing challenges that once worried investors are now demonstrating Novo's ability to scale production effectively while maintaining quality standards across both injection and oral formulations.
Efficacy Data Becomes Key Differentiator
Doubts about Lilly's lock on the market emerged last summer when the company said its pill helped people lose about 12% of their body weight, on average, while Novo pounced on the opportunity and started to highlight the efficacy of oral semaglutide, which delivered almost 17% weight loss in a separate trial.
This efficacy gap has proven crucial in the market's reception of both pills. When the Wegovy pill was approved around the New Year, Novo and its telehealth partners rolled out a high-profile promotional blitz, capitalizing on their superior weight loss data to capture market share.
The 5-percentage-point difference in weight loss outcomes has become a significant talking point for healthcare providers and patients weighing their options between oral GLP-1 medications.
Expanding the Total Addressable Market
The Wegovy pill — and now Lilly's own oral drug — are helping to expand the GLP-1 market, reaching patients who wouldn't have otherwise sought treatment due to a fear of needles or difficulty accessing the injections, which used to cost much more than today's pills for many patients.
People are choosing GLP-1 pills "by a huge factor" more than shots through telehealth platform Sesame, with president and co-founder Michael Botta attributing the preference to the lower price of the pills versus the shots and the fact that people are more comfortable trying oral drugs than going straight to shots.
This market expansion is particularly significant for increasing access across different patient populations. "There's no question that the launch of oral medications has improved access," said LifeMD CEO Justin Schreiber.
The oral format has removed two major barriers to treatment: injection anxiety and higher costs associated with injectable medications. This accessibility improvement is creating opportunities for people who might never have considered GLP-1 treatment before.
Investment Implications and Future Outlook
Investors will be on high alert for any data related to the Wegovy pill and whether Novo stands by the gloomy forecast it issued in February, when it said sales and profits will both decline by 5% to 13% in 2026. The strong early performance of the oral formulation may force the company to revise these projections upward.
"Yes it's shaking things up, but I still think Lilly has enough components to excel," said BMO's Seigerman. "And while Novo may win with this, they need more than one win to be the champion."
The competitive dynamics are evolving rapidly as both companies adjust their strategies based on real-world market response. Wall Street analysts are closely watching prescription trends and market share data to gauge the long-term impact of oral GLP-1 competition.
What This Means for You
If you're considering GLP-1 medications for weight loss, the success of oral options means you now have more choices than ever. The Wegovy pill's strong uptake suggests that oral GLP-1s are genuinely meeting patient needs, particularly for those who prefer not to use injections.
The competitive pressure between Novo and Lilly is driving innovation and potentially better pricing. With both companies now offering oral options, you can compare telehealth providers to find the most convenient and affordable way to access these treatments. The expansion of the oral market means more people are finding GLP-1 treatment accessible for the first time.
When evaluating your options, consider discussing both the efficacy differences and your personal preferences with a healthcare provider. The cost considerations between oral and injectable formulations may also factor into your decision-making process.
Sources
Novo Nordisk's head start on GLP-1 pills forces investors to rethink Eli Lilly's dominance - CNBC analysis of early Wegovy pill market performance
Eli Lilly Gets Speedy FDA Nod for Oral GLP-1 Drug - MedCity News coverage of Foundayo approval
The brief reign of Novo Nordisk's Wegovy pill as the lone oral GLP-1 approved for obesity has ended - FiercePharma on the competitive dynamics between oral GLP-1s